BioWorld

Jan. 27, 2009

View Archived Issues

Biotech Reveling in the Stem Cell Effect, Embryonic or not

It's never been so good to be working in the embryonic stem cell space. (BioWorld Today) Read More

Pfizer $68B Bid for Wyeth Leaves Crucell at the Altar

Nearly a Decade Later, RECIST Rules Get Their First Makeover

Investors Balk as Altus Drops Trizytek and Cuts 75% of Staff

Forma Getting up to $54M in Cubist Antibacterial Deal

AC Immune Gets $35M for Alzheimer's Pipeline

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Atai Therapeutics patents new 5-HT2 receptor agonists

BioWorld Science

Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.